Artifact GuideEU MDR

EU MDR Device Classification Guide

Use intended purpose and Annex VIII to decide whether a product is class I, IIa, IIb, or III under Regulation (EU) 2017/745.

This guide focuses on duration, invasiveness, active-device status, software Rule 11, conformity route consequences, and the evidence needed to defend the classification rationale.

Back to main artifactReview sources
Author
Sorena AI
Published
May 9, 2026
Updated
May 9, 2026
Sections
5

Structured answer sets in this page tree.

Primary sources
4

Cited legal and guidance references.

Publication metadata
Sorena AI
Published May 9, 2026
Updated May 9, 2026
Overview

EU MDR classification is a risk-based legal and technical decision. Start from the manufacturer-stated intended purpose, apply the Annex VIII definitions and rules, use the highest applicable class where several rules fit, and keep a rationale that links the device claims, evidence, and conformity assessment route.

Section 1

Start with intended purpose

The classification record should begin with the intended purpose supplied by the manufacturer: indications, target patient population, users, use environment, body site, mode of action, duration of contact, and whether the product is standalone software, an accessory, a system component, or a device in its own right.

Do not classify from marketing shorthand. Check labels, instructions for use, clinical claims, software outputs, risk-management files, and product variants for claims that change the intended medical purpose. A new diagnostic, monitoring, therapeutic, invasive, implantable, or active function can move the device into a different Annex VIII rule or class.

  • Record the exact device model, Basic UDI-DI where available, version or configuration, and the claims being classified.
  • Separate accessories from the parent device: Annex VIII says accessories are classified in their own right.
  • For combined use, classify each device separately unless the MDR treats the combination as a system, procedure pack, or a device in its own right.
  • If more than one rule or sub-rule applies to the intended purpose, use the strictest applicable outcome.
Sources for this answer
Regulation (EU) 2017/745 on medical devices
Annex VIII makes intended purpose the starting point for classification and requires the highest class where several rules apply.
MDCG 2021-24 - Guidance on classification of medical devices
MDCG classification guidance explains the practical classification method and risk-based criteria used with Annex VIII.
Section 2

Apply Annex VIII criteria

Annex VIII is not a checklist of product categories; it is a sequence of definitions, implementing rules, and device-type rules. Work through duration, invasiveness, body site, active-device function, substances, special materials, and software before selecting the class.

Duration is measured as continuous use: transient means less than 60 minutes, short term means 60 minutes to 30 days, and long term means more than 30 days. For replaceable devices, Annex VIII can count accumulated use where the manufacturer intends immediate replacement with another of the same type.

  • For non-invasive devices, start with Rule 1, then check channelling or storage, biological or chemical modification, contact with injured skin or mucous membrane, and special substance rules.
  • For invasive devices, identify body-orifice use, surgical invasiveness, implantable status, duration, body site, absorption, biological effect, ionising radiation, medicinal product administration, and direct contact with the heart, central circulatory system, or central nervous system.
  • For active devices, decide whether the device administers or exchanges energy, diagnoses or monitors, emits ionising radiation, administers or removes substances, controls an active implantable device, or falls into the active-device fallback.
  • Check special rules for ancillary medicinal substances, contraception or sexually transmitted disease prevention, cleaning or sterilisation, X-ray image recording, non-viable tissues or cells, nanomaterials, inhalation administration, substance-based devices, and active therapeutic devices with integrated diagnostic functions.
Sources for this answer
Regulation (EU) 2017/745 on medical devices
Annex VIII defines duration, invasive and active-device concepts, implementing rules, and Rules 1-22.
MDCG 2021-24 - Guidance on classification of medical devices
MDCG 2021-24 gives rule-by-rule classification explanations and examples for non-invasive, invasive, active, and special-rule devices.
Section 3

Handle software and Rule 11

Software classification needs two decisions before the class outcome: whether the software qualifies as medical device software under the MDR, and whether it drives or influences a hardware device or is independent. Annex VIII treats software as an active device, and software that drives or influences another device falls within the same class as that device.

Rule 11 applies to software that provides information used for diagnostic or therapeutic decisions or monitors physiological processes. The risk analysis should explain the significance of the software output, the healthcare situation or patient condition, the intended population, context of use, and likely impact of incorrect information.

  • Class IIa is the baseline for software providing information used for diagnostic or therapeutic decisions.
  • Class III applies where those decisions may cause death or irreversible deterioration of health.
  • Class IIb applies where those decisions may cause serious deterioration of health or surgical intervention.
  • Software monitoring physiological processes is class IIa unless it monitors vital physiological parameters where variations could immediately endanger the patient, in which case it is class IIb.
  • All other software is class I, but only after documenting why the higher Rule 11 branches and any hardware-driving rule do not apply.
Sources for this answer
Regulation (EU) 2017/745 on medical devices
Annex VIII Rule 11 provides the binding MDR class outcomes for medical device software.
MDCG 2019-11 - Qualification and classification of software
MDCG 2019-11 explains software qualification, software driving or influencing device use, and Rule 11 classification logic.
Recommended next step

Turn MDR classification into a reviewable evidence file

Use Sorena to convert intended-purpose claims, Annex VIII rules, Rule 11 software logic, and conformity route consequences into a cited classification rationale.

Research workflow
Open Research Copilot

Check MDR classification questions against cited sources and produce reusable rationale drafts.

Explore next step
Talk to Sorena
Talk through implementation

Review your device facts, Annex VIII analysis, conformity route, and evidence gaps.

Explore next step
Section 4

Map the class to conformity assessment

Classification is not just a label. It determines the conformity assessment route, notified body involvement, technical documentation review depth, clinical evidence expectations, certificate content, and the resources needed before market placement.

As a general rule under the MDR recitals, class I conformity assessment is carried out under the manufacturer's responsibility because of lower vulnerability, while class IIa, IIb, and III devices require an appropriate level of notified body involvement. Specific class I cases can still require notified body involvement, such as sterile condition, measuring function, reusable surgical instruments, or software class changes triggered by Annex VIII.

  • For class I, confirm whether the device is plain class I or has a class I feature that requires notified body involvement for limited aspects.
  • For class IIa and IIb, plan notified body selection, QMS assessment, representative technical documentation sampling, and clinical evaluation evidence early.
  • For class III, expect the highest scrutiny, including technical documentation assessment and any applicable consultation or expert-panel pathway.
  • For each route, align the classification memo with the EU declaration of conformity, technical documentation, clinical evaluation, PMS/PMCF planning, UDI/device registration, and certificate scope.
Sources for this answer
Regulation (EU) 2017/745 on medical devices
The MDR links class outcomes to conformity assessment procedures, notified body involvement, technical documentation, and certificates.
European Commission - Notified bodies for medical devices
Commission page explaining that notified bodies assess conformity when third-party intervention is required and that designated bodies are listed publicly.
Section 5

Keep a defensible classification rationale

A classification rationale should let a reviewer reproduce the decision without interviewing the product team. The document should show the intended purpose reviewed, the Annex VIII definitions applied, each candidate rule considered, the selected class, the conformity route consequence, and the evidence that supports or excludes higher-risk rules.

Reopen the rationale when claims, labels, instructions for use, software functionality, energy delivery, body contact, material composition, duration of use, target population, clinical use environment, or combination with another device changes. The same trigger list should be connected to design-change control and notified body communication where certificates or approved technical documentation are affected.

  • Include a rule table with columns for fact pattern, Annex VIII rule, class result, reason included or excluded, and evidence reference.
  • Attach intended-purpose evidence: label and IFU extracts, clinical claims, software functional specification, risk analysis, usability assumptions, and product-variant boundaries.
  • For software, retain the qualification decision, Rule 11 branch, hardware-driving or influencing analysis, patient-condition analysis, and failure-impact rationale.
  • For active or invasive devices, retain body-contact, duration, energy, substance, absorption, material, and body-site evidence.
  • Tie the final class to conformity assessment planning: notified body need, application scope, certificate scope, technical documentation sampling, and clinical evaluation depth.
Sources for this answer
Regulation (EU) 2017/745 on medical devices
MDR technical documentation and clinical investigation content require intended purpose, risk classification, and applicable classification rule references.
MDCG 2021-24 - Guidance on classification of medical devices
MDCG 2021-24 supports a documented, rule-by-rule rationale for applying Annex VIII to device facts.
Primary sources

References and citations

European Commission - Notified bodies for medical devices
health.ec.europa.eu
Referenced sections
  • Commission page explaining that notified bodies assess conformity when third-party intervention is required and that designated bodies are listed publicly.
"to assess the conformity of certain products"
MDCG 2019-11 - Qualification and classification of software
ec.europa.eu
Referenced sections
  • MDCG 2019-11 explains software qualification, software driving or influencing device use, and Rule 11 classification logic.
"MDSW should be classified in the same way, regardless of the software's location"
Regulation (EU) 2017/745 on medical devices
eur-lex.europa.eu
Referenced sections
  • MDR technical documentation and clinical investigation content require intended purpose, risk classification, and applicable classification rule references.
"risk classification and applicable classification rule pursuant to Annex VIII"
Related guides

Explore more topics

Custom-made medical devices under the EU MDR | EU MDR FAQ
Concise EU MDR FAQ on custom-made device definition, mass-produced exclusions, Annex XIII statements, documentation, conformity assessment, PMS, vigilance, and records to retain.
EU MDR Annex II and III Technical Documentation
Build an MDR technical documentation index for Annex II device files and Annex III post-market surveillance evidence, including GSPR, risk, clinical, PMS, UDI, and EUDAMED records.
EU MDR Annex VIII Classification Guide
Classify EU MDR medical devices under Annex VIII using intended purpose, duration, invasiveness, active device and software rules, and conformity assessment impact.
EU MDR Annex XVI products without a medical purpose
source-linked EU MDR guide for Annex XVI products: listed product groups, common specifications, clinical evidence, notified-body route, UDI, EUDAMED, PMS, and vigilance evidence before launch.
EU MDR Applicability Test
Test whether a product, accessory, software function, or Annex XVI product falls under the EU Medical Device Regulation, and record the evidence for the next classification step.
EU MDR change assessment workflow
Assess EU MDR device, design, software, intended purpose, QMS, clinical, PMS, UDI, classification, and notified-body impacts before releasing a medical device change.
EU MDR Checklist for Medical Device Compliance
Practical EU MDR checklist covering qualification, classification, conformity assessment, technical documentation, GSPR, clinical evidence, UDI, EUDAMED, PMS, vigilance, QMS, and legacy transition evidence.
EU MDR classification workflow
A concrete EU MDR classification workflow for intended purpose, device or accessory qualification, Annex VIII rule selection, Rule 11 software review, class outcome, and notified body impact.
EU MDR Clinical Evaluation Overview
EU MDR clinical evaluation overview covering Article 61, Annex XIV, clinical data sources, equivalence, PMCF, CER evidence, notified body review, GSPR, and benefit-risk support.
EU MDR Clinical Evaluation Report Template
A source-linked EU MDR clinical evaluation report template covering intended purpose, GSPR linkage, clinical data appraisal, equivalence limits, PMCF, conclusions, and reviewer signoff.
EU MDR clinical evidence guide
source-linked EU MDR guide to clinical evaluation, clinical investigations, equivalence, PMCF, GSPR support, technical documentation, and notified-body review.
EU MDR compliance obligations
EU MDR compliance guide for device qualification, classification, conformity assessment, QMS, technical documentation, UDI, EUDAMED, PMS, vigilance, and legacy transition controls.
EU MDR conformity route workflow
source-linked EU MDR workflow for classifying a device, choosing the conformity assessment route, preparing technical and QMS evidence, and reaching certificate, DoC, UDI, EUDAMED, and CE outputs.
EU MDR deadlines and compliance calendar
Grounded EU MDR calendar for application, legacy-device transition, UDI, EUDAMED, and recurring QMS, technical documentation, clinical, PMS, vigilance, certificate, and change reviews.
EU MDR EUDAMED and UDI registration
source-linked MDR guide to Basic UDI-DI, UDI-DI, EUDAMED device registration, actor roles, labels, technical documentation, and UDI data governance.
EU MDR FAQ: qualification, evidence, UDI, and transition
Concise EU MDR FAQ covering device qualification, software classification, accessories, custom-made devices, clinical evidence, UDI, EUDAMED, notified bodies, significant changes, and legacy transition.
EU MDR Legacy Device Transition
source-linked EU MDR legacy device transition guide covering Regulation (EU) 2023/607 conditions, certificate validity, significant-change limits, surveillance, PMS, vigilance, QMS, and evidence records.
EU MDR notified body route selection
Choose an EU MDR conformity assessment route by device class, Article 52 option, notified body designation scope, QMS readiness, technical documentation, clinical evidence, and certificate evidence.
EU MDR penalties and enforcement risk
source-linked EU MDR penalties and enforcement-risk guide covering Article 113, Member State penalty rules, market restrictions, recalls, certificate consequences, and evidence.
EU MDR PMS and Vigilance Guide
EU MDR guide to post-market surveillance, PMCF updates, PMS reports, PSURs, serious incident reporting, FSCA/FSN handling, trend reporting, and evidence records.
EU MDR PMS and vigilance records
source-linked EU MDR guide to PMS plans, PMS reports, PSURs, PMCF updates, serious incident and FSCA reporting, trend reporting, and EUDAMED evidence handling.
EU MDR PMS Plan Template for Medical Devices
A source-linked EU MDR post-market surveillance plan template covering device scope, PMS data sources, PMCF linkage, vigilance, trend reporting, PMSR or PSUR outputs, roles, cadence, and evidence records.
EU MDR QMS and technical file evidence map
Map EU MDR Article 10 QMS duties to Annex II and Annex III technical documentation, PMS, vigilance, UDI records, and notified-body review evidence.
EU MDR QMS requirements under Article 10
EU MDR QMS guide for Article 10 manufacturer controls covering regulatory strategy, design, risk, clinical evaluation, PMS, vigilance, UDI, suppliers, CAPA, and conformity records.
EU MDR qualification and borderline products
EU MDR qualification guide for medical purpose claims, accessories, software, Annex XVI products, and borderline routes to classification and conformity assessment.
EU MDR qualification workflow
A concrete EU MDR workflow for deciding whether a product is a medical device, accessory, Annex XVI product, IVD interface, medicinal-product interface, or non-MDR product before classification and conformity assessment.
EU MDR requirements checklist
Concrete EU MDR requirements for medical-device scope, classification, GSPR, conformity assessment, technical documentation, QMS, clinical evidence, UDI, EUDAMED, PMS, vigilance, and economic-operator records.
EU MDR Rule 11 software classification
Classify MDR medical device software under Rule 11 using intended purpose, diagnosis or therapy decision impact, physiological monitoring, conformity route, clinical evidence, and software-change records.
EU MDR significant changes FAQ: legacy-device transition and notified-body review
FAQ on MDR significant changes for legacy devices, including intended-purpose, design, software, material, sterilisation, clinical, QMS, notified-body, and evidence impacts.
EU MDR Transition Timelines: practical guide
EU Medical Device Regulation guide to Transition Timelines with scope decisions, owner actions, evidence records, source-linked citations, and practical next steps.
EU MDR UDI and EUDAMED registration guide
EU MDR guide to Basic UDI-DI, UDI-DI, UDI carriers, EUDAMED actor and device registration, change impacts, and evidence governance.
EU MDR vigilance reporting workflow
Concrete EU MDR vigilance workflow for incident intake, serious incident assessment, FSCA and FSN handling, trend reporting, EUDAMED caveats, CAPA, PMS, clinical evaluation updates, and records.
How should Basic UDI-DI and UDI-DI be assigned under the EU MDR? | EU MDR FAQ
EU MDR FAQ explaining what Basic UDI-DI and UDI-DI identify, how they connect to UDI carriers, EUDAMED records, change triggers, and retained evidence.
MDR vs AI Act for medical-device software
Compare MDR software qualification, classification, clinical evidence, QMS, PMS, UDI, EUDAMED, and notified-body evidence boundaries against cautiously scoped AI Act overlap.
MDR vs GPSR: medical-device boundary checks
Compare MDR medical-device scope with general product-safety fallback questions for borderline, non-medical, and Annex XVI products.
MDR vs IVDR: medical devices and IVDs compared
Compare EU MDR and IVDR scope, classification, conformity routes, technical documentation, clinical or performance evidence, UDI, EUDAMED, PMS, and vigilance.
MDR vs Product Liability Directive evidence comparison
Compare EU MDR market-access evidence with Product Liability Directive exposure without treating compliance records as a liability outcome.
What should an EU MDR PMCF plan and report cover? | EU MDR FAQ
Under the EU MDR, PMCF is part of PMS and clinical evaluation. See what the plan, activities, report, updates, and retained evidence should cover.
What should manufacturers do when an EU MDR classification changes? | EU MDR FAQ
Concise EU MDR FAQ on classification changes, intended purpose, software, notified-body route impact, certificates, technical documentation, and retained evidence.
When can clinical equivalence be used under the EU MDR?
EU MDR FAQ on clinical equivalence, including technical, biological, and clinical characteristics, access to equivalent-device data, class III and implantable-device limits, clinical evaluation, PMCF, and retained evidence.
When do software or products make medical purpose claims under the EU MDR? | EU MDR FAQ
EU MDR FAQ on medical purpose claims, intended purpose evidence, software qualification, Annex XVI contrasts, and records to keep.
When is a PSUR required under the EU MDR and what should it contain? | EU MDR FAQ
EU MDR FAQ on PSUR scope, content, update cadence, PMS and PMCF links, notified-body handling, EUDAMED submission, and evidence to retain.
When is an accessory regulated under the EU MDR? | EU MDR FAQ
EU MDR FAQ on when an article is a medical device accessory, how intended purpose affects classification, and what evidence to keep.
When is software regulated as SaMD under the EU MDR? | EU MDR FAQ
Concise EU MDR FAQ on software qualification, intended medical purpose, Rule 11 classification, modules, clinical evidence, change assessment, UDI, and EUDAMED.
Which devices need an SSCP under the EU MDR and what should it include? | EU MDR FAQ
EU MDR FAQ on when an SSCP is required, who prepares, validates, uploads, and updates it, and what evidence should support the summary.
Which EUDAMED modules matter under the EU MDR? | EU MDR FAQ
EU MDR FAQ mapping EUDAMED modules to actor registration, UDI/device data, certificates, clinical investigations, vigilance/PMS, market surveillance, and practical records.